- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application | 338 | PR Newswire | SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced... ► Artikel lesen | |
| Fr | MABWELL-B (02493): VOLUNTARY ANNOUNCEMENT REGARDING THE RECEIPT OF U.S. FDA CLEARANCE FOR THE CLINICAL TRIAL APPLICATION OF 9MW5211 INJECTION | 1 | HKEx | ||
| 07.05. | MABWELL-B Plans to Apply to NAFMII to Issue Up to RMB1B Private Placement Debt Financing Instruments | 1 | AASTOCKS | ||
| 06.05. | MABWELL-B (02493): PROXY FORM FOR THE 2026 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, JUNE 1, 2026 | - | HKEx | ||
| 06.05. | MABWELL-B (02493): NOTICE OF 2026 SECOND EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| MABWELL SHANGHAI BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 06.05. | MABWELL-B (02493): CIRCULAR FOR 2026 SECOND EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 06.05. | MABWELL-B (02493): ANNOUNCEMENT - APPLICATION FOR THE REGISTRATION AND ISSUANCE OF TARGETED DEBT FINANCING INSTRUMENTS | 1 | HKEx | ||
| 06.05. | MABWELL-B (02493): NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS TO NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 06.05. | MABWELL-B (02493): NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS TO REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 30.04. | MABWELL-B (02493): EXEMPTION UNDER RULE 13.46(2) OF THE LISTING RULES REGARDING 2025 ANNUAL REPORT | - | HKEx | ||
| 30.04. | MABWELL-B (02493): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | 1 | HKEx | ||
| 28.04. | MABWELL-B (02493): OVERSEAS REGULATORY ANNOUNCEMENT - MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. 2026 FIRST QUARTERLY REPORT | 1 | HKEx | ||
| 28.04. | MABWELL-B Closes Up 0.6% to $27.8 | 4 | AASTOCKS | ||
| 28.04. | Empowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEX | 275 | JCN Newswire | HONG KONG, Apr 28, 2026 - (ACN Newswire) - Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the... ► Artikel lesen | |
| 28.04. | MABWELL-B Closes Up 1.3% to $28 at Midday | 1 | AASTOCKS | ||
| 28.04. | MABWELL-B Opens Up 2.4% to $28.3 on Debut | 3 | AASTOCKS | ||
| 28.04. | SSE and SZSE to Add Mabwell Bioscience-B to Stock Connect Eligible Securities List Effective Today | 1 | AASTOCKS | ||
| 27.04. | MABWELL-B (02493): ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS | 1 | HKEx | ||
| 27.04. | Mabwell-B Closes Up 3.1% to $28.5 on Gray Mkt | 4 | AASTOCKS | ||
| 27.04. | Mabwell-B Opens Up 2% to $28.2 on Gray Mkt | 1 | AASTOCKS |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | EQS-News: Evotec SE: Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik | EQS-News: Evotec SE
/ Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung
Evotec gibt Ergebnisse für das erste Quartal 2026 bekannt: Transformation gewinnt an Dynamik... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | 0,00 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | 0,00 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | +4,83 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update | ||
| TANGO THERAPEUTICS | 25,510 | +8,55 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| C4 THERAPEUTICS | 3,660 | +15,46 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| BIONTECH | 78,95 | -1,07 % | Curevac-Gründer wirft Biontech Täuschung vor | TÜBINGEN/MAINZ (dpa-AFX) - Nach der Übernahme des Biotechunternehmens Curevac durch Biontech wirft Curevac-Gründer Ingmar Hoerr dem Konkurrenten Täuschung vor. Hintergrund sind die Schließungspläne... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | -0,11 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | 0,00 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,850 | -8,24 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ERASCA | 10,450 | +0,67 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
MABWELL SHANGHAI BIOSCIENCE CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MABWELL SHANGHAI BIOSCIENCE CO LTD finden Sie auf Wallstreet Online.